BidaskClub lowered shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a sell rating to a strong sell rating in a research note published on Friday.

Separately, Zacks Investment Research raised Achillion Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, June 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $4.38.

NASDAQ ACHN traded up $0.05 on Friday, reaching $3.13. 952,353 shares of the company were exchanged, compared to its average volume of 1,459,196. The firm has a market capitalization of $510.00 million, a P/E ratio of -5.05 and a beta of 1.27. Achillion Pharmaceuticals has a fifty-two week low of $2.33 and a fifty-two week high of $4.63.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.01. On average, equities research analysts predict that Achillion Pharmaceuticals will post -0.52 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACHN. Acadian Asset Management LLC acquired a new position in Achillion Pharmaceuticals during the second quarter worth $135,000. Cubist Systematic Strategies LLC acquired a new position in shares of Achillion Pharmaceuticals in the 2nd quarter valued at $147,000. BlueMountain Capital Management LLC acquired a new position in shares of Achillion Pharmaceuticals in the 2nd quarter valued at $159,000. Element Capital Management LLC acquired a new position in shares of Achillion Pharmaceuticals in the 1st quarter valued at $163,000. Finally, New York State Common Retirement Fund lifted its stake in shares of Achillion Pharmaceuticals by 24.1% in the 1st quarter. New York State Common Retirement Fund now owns 146,800 shares of the biopharmaceutical company’s stock valued at $545,000 after purchasing an additional 28,500 shares during the last quarter. 78.36% of the stock is currently owned by institutional investors.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Featured Article: What are earnings reports?

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.